Following U.S. Stocks were among the “Top Losers” during Monday’s trade: Hecla Mining Company (NYSE:HL),Eclipse Resources Corp (NYSE:ECR), Galena Biopharma Inc (NASDAQ:GALE), EXCO Resources Inc (NYSE:XCO)

Their insights are depicted underneath:

Hecla Mining Company (NYSE:HL)’s shares dwindled -6.06%, and closed at $2.79.

Through BUSINESS WIRE, on February 18, Hecla Mining Co. (HL), declared 2014 sales of $500.8 million and gross profit of $85.2 million, with net revenue applicable to ordinary stockholders of $17.3 million, or $0.05 per basic share, and an adjusted net revenue applicable to ordinary stockholders of $5.6 million, or $0.02 per basic share.

FULL YEAR 2014 HIGHLIGHTS - comparison to 2013:

• Record sales of $500.8 million, a 31% raise.2
• Silver equivalent production of 34.5 million ounces, the highest in the corporation’s history.3
• A 24% raise in silver production with a 30% decrease in per ounce cash costs, after by-product credits.
• A 56% raise in gold production with 128,244 ounces produced at Casa Berardi at an average cash cost, after by-product credits, per gold ounce of $826, a 13% reduction.4
• Adjusted EBITDA of $174.4 million, a 29% raise.5
• Operating cash flow of $83.1 million, which comprises the final $55.4 million payment to satisfy the Coeur d’Alene Basin litigation settlement, a 212% raise, and the third highest level in the corporation’s history.
• Highest year-end proven and probable silver reserve levels in the corporation’s history for the 9th successive year.
• Cash and cash equivalents of $209.7 million at December 31, 2014.

Hecla Mining Corporation (HL) is a leading low-cost U.S. silver producer with operating mines in Alaska and Idaho, and is a growing gold producer with an operating mine in Quebec, Canada. The Corporation also has exploration and pre-development properties in five world-class silver and gold mining districts in the U.S., Canada and Mexico, and an exploration office and investments in early-stage silver exploration projects in Canada.

Eclipse Resources Corp (NYSE:ECR), declined -5.99%, and closed at $6.12.

Through BUSINESS WIRE, Eclipse Resources Corporation (ECR) declared its 2014 and fourth quarter 2014 financial and operational results. Highlights for the year and fourth quarter comprise:

• 2014 adjusted net production averaged about 73.5 MMcfe(1) per day for the year, contrast to 4.5 MMcfe per day for 2013
• Fourth quarter 2014 adjusted net production raised to 130.7 MMcfe(1) per day, representing a 52% raise in production as contrast to the third quarter of 2014
• 2014 average daily net liquids production was 3,098 barrels per day, surpassing the midpoint of the Corporation’s formerly issued guidance and representing 26% of total net production
• Fourth quarter 2014 average daily net liquids production was 5,480 barrels per day, or 27% of total net production, and represented an raise of 78% contrast to the third quarter of 2014
• 2014 adjusted proceeds grew to $138.0 million(1), representing a 967% raise from 2013, and grew to $52.6 million in the fourth quarter of 2014, a 45% raise relative to the third quarter of 2014
• Adjusted EBITDAX(1) grew to $62.4 million for the year and was $25.9 million for the fourth quarter, representing a 98% raise relative to the third quarter of 2014
• Unit operating costs were $1.27 per Mcfe for the year and fourth quarter 2014 unit operating costs were $1.17 per Mcfe, a $0.28 reduction relative to the midpoint of guidance and a $0.23 reduction relative to the third quarter of 2014
• 2014 capital expenditures were $809 million, in-line with our guidance for the year
• Proved reserves at the end of 2014, raised by 353% to about 355.8 Bcfe (28% liquids) with a pre-tax PV-10(1) of $509.4 million
• 28 gross (22 net) operated and 65 gross (10 net) non-operated Utica Shale wells turned to sales during 2014 and 11 gross (9 net) operated and 19 gross (2 net) non-operated Utica Shale wells turned to sales during the fourth quarter of 2014
• Reduced drilling times and raised accomplished stages per day with average drilling times reduced by 36% to 16 days as contrast to the IPO plan of 25 days, and with average accomplished stages per day improving by 67% from 3 stages per day to 5 stages per day
• Subsequent to year-end, Eclipse Resources closed its declared sale of ordinary equity raising net proceeds of about $434 million and providing the Corporation with about $575 million of pro forma liquidity at year-end.

Eclipse Resources is an independent exploration and production corporation engaged in the attainment and development of oil and natural gas properties in the Appalachian Basin, counting the Utica Shale and Marcellus Shale.

Galena Biopharma Inc (NASDAQ:GALE) dipped -5.85%, and closed at $1.77.

Through GLOBE NEWSWIRE, Galena Biopharma, Inc. (GALE), a biopharmaceutical corporation developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, stated its financial results for the quarter and year ended December 31, 2014 and offered a business update.

FINANCIAL HIGHLIGHTS;.

The corporation recognizes proceed from the sale of Abstral to wholesale pharmaceutical distributors, net of product-related discounts, allowances, product returns, rebates, chargebacks, and patient assistance benefits, as applicable. Net proceed was $3.2 million in the fourth quarter of 2014 and $9.3 million for the year ended December 31, 2014, contrast to $1.3 million and $2.5 million, respectively, for the same periods of 2013.

Operating loss for the fourth quarter of 2014 was $11.4 million, counting $1.0 million in stock based compensation, and $52.2 million, counting $5.4 million in stock-based compensation charges, for the year ended December 31, 2014, contrast to $12.4 million, counting $1.6 million in stock-based compensation, and $33.8 million, counting $2.9 million in stock based compensation, respectively, for the same periods in 2013. The rise in net operating loss year-over-year is primarily the result of our raised activity and enrollment in our Phase 3 PRESENT trial for NeuVax, our investigator sponsored trials for NeuVax, and our Phase 2 trial for GALE-401, in addition to raised selling and marketing expenses associated with the growth of our commercial activities.

Other revenue or expense comprises non-cash charges related to changes in the fair value estimates of the corporation’s warrant liabilities and contingent purchase price liability, and the realized gain from the sale of marketable securities. The non-cash benefit related to the changes in values of our warrant and contingent purchase price liabilities for the fourth quarter of 2014 was $3.6 million and $16.7 million for the year ended December 2014, as compared to non-cash charges of $37.2 million and $44.9 million, respectively, for the same periods in 2013, respectively.

Galena Biopharma, Inc. (GALE) is a biopharmaceutical corporation developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena’s development portfolio ranges from mid- to late-stage clinical assets, counting a robust immunotherapy program led by NeuVax(TM) (nelipepimut-S) presently in an international, Phase 3 clinical trial.

EXCO Resources Inc (NYSE:XCO), dropped -5.82%, and closed at $1.78. The company has the market capitalization of $517.41M. The beta value of the stock is 1.22. On the other hand the stock’s volatility for the week is 5.95%, and for the month is 8.03%. The stock price to book value is $0.95, however price to sale value is $0.74. Analyst’s mean recommendation regarding this stock is 4.00. (where 1=Buy, 5=Sale).

EXCO Resources, Inc., an independent oil and natural gas corporation, engages in the attainment, exploration, exploitation, development, and production of onshore oil and natural gas properties with a focus on shale resource plays in the United States.